This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

Home
Issues
About
Contact
Register
Login

Drei-Jahres-Daten für IL-17A- und IL-17F-Inhibitor bei mittelschwerer bis schwerer Plaque-PsoriasisBack

To view this article, please confirm that you are a healthcare professional by clicking 'Confirm' below.

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Register

Sign up for free access to Wiley’s Key Opinions in Medicine to keep up to date with latest trends and key developments within your specialty area.

Web design and marketing agency Leamington Spa

Most Read Issues